Proteomics International's PromarkerD Diabetes Test Gets Key Breakthrough in US Market

Proteomics International is making significant strides in bringing its PromarkerD diabetes-related blood test to the US market. The company has successfully secured an American Medical Association PLA billing code, allowing doctors to order and facilities to bill for the test, a crucial step towards broader market adoption. This breakthrough comes as the company prepares to roll out the test nationwide, with patients and healthcare providers able to submit claims for reimbursement from October 1. PromarkerD was designed to identify diabetic patients at risk of developing kidney disease up to four years before symptoms appear, with a patented next-generation test accurately predicting kidney function decline in up to 86% of patients showing no symptoms.

Key Takeaways:

• The PromarkerD diabetes-related blood test has been assigned an American Medical Association PLA billing code, enabling doctors to order and facilities to bill for the test.
• Patients and healthcare providers can submit claims for reimbursement from October 1, marking a significant step towards broader market uptake.
• PromarkerD accurately predicted kidney function decline in up to 86% of patients showing no symptoms, replicating results from earlier clinical trials.
• The test was designed to identify diabetic patients at risk of developing kidney disease up to four years before symptoms appear.
• Catching early signs of diabetic kidney disease allows patients to receive preventive care, avoiding costly and life-threatening end-stage kidney disease.
• The test has the potential to help over 32 million Americans living with type 2 diabetes, given more than half of all adults with diabetes in the US will develop kidney complications.
• PromarkerD's commercial release in the US follows the company's official launch of the next-gen test at the annual meeting of the American Diabetes Association last month.
• The company has presented its recommended US pricing to the Centres for Medicare and Medicaid Services for tests ordered from next year.

Statistics:

• Promotion International's PromarkerD test has a 86% accuracy rate in predicting kidney function decline in patients showing no symptoms.
• Over 32 million Americans live with type 2 diabetes, with more than half at risk of developing kidney complications.
• Diabetic kidney disease contributes to over $130 billion in annual healthcare costs, more than a quarter of the nation's Medicare budget.

Sources:

• "PromarkerD diabetes-related blood test gets key breakthrough in US market" by Matt Birney, Bull & Bears magazine
• Proteomics International official announcement "Proteomics International USA receives dedicated PLA billing code for PromarkerD in the US market"
• American Diabetes Association (ADA) annual meeting press release "Proteomics International Unveils Next-Gen PromarkerD Test for Diabetic Kidney Disease"
• Centres for Medicare and Medicaid Services (CMS) press release "CMS to release preliminary pricing for PromarkerD tests ordered from next year"